10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
10x Genomics (TXG) announced a research collaboration with Fred Hutchinson Cancer Center to investigate single cell and spatial applications in cancer. This is 10x's first clinical research initiative extending beyond solid tumors into blood cancers.
The bladder cancer project plans to use Flex Apex and Xenium, with expansion to Atera planned, to study samples from patients with advanced disease. It aims to connect drug target expression and features of the tissue surrounding tumors with treatment response and clinical outcomes, exploring biomarkers that could eventually inform therapy selection.
The second project plans to use Flex Apex to investigate whether analysis of individual cells can improve detection of residual leukemia cells after treatment for acute myeloid leukemia. The teams also plan a framework for future clinical reporting to explore how these biological features could support cancer treatment planning.
10x Genomics (TXG) announced Sentira, a cloud analysis platform, with Sentira Spatial now available through Early Access.
Access is free for researchers using Xenium or Atera. 10x says NVIDIA-accelerated computing can reduce spatial analysis cycles from hours on CPU alternatives to minutes. Atera began shipping to customers on September 29, 2026.
Sentira Spatial is expected to launch commercially in early 2027 as a paid platform with consumption-based credit pricing. Enterprise subscription options are planned.
10x Genomics (TXG) has begun worldwide commercial shipments of Atera, its spatial biology platform for research customers. Booked orders exceeded the 40 instruments the company expected to ship in 2026, a threshold it disclosed on its second-quarter earnings call. In five months, projects were booked across more than 100 customers. Nearly all of the world’s top 20 biopharma companies by research and development spending are purchasing Atera systems or services through 10x’s Catalyst Research Services lab.
The Allen Institute plans to use three instruments for research in immunology, neuroscience and synthetic biology. The ASTRA consortium plans to use Atera to expand its cancer atlas to 5,000 tumors over the next two years. 10x is also preparing to run its first customer samples through Catalyst Research Services. Its Atera roadmap includes planned mouse whole-transcriptome capabilities and other future additions.
Lunit and 10x Genomics (TXG) are collaborating to integrate Lunit's AI-enabled H&E pathology analysis with 10x Genomics' spatial molecular technologies for oncology clinical research. Lunit SCOPE IO will be incorporated into 10x's oncology biomarker discovery workflow to analyze Hematoxylin and Eosin pathology images alongside spatial molecular data from 10x's Xenium and Atera platforms.
The combined approach is intended to help researchers relate tissue morphology to tumor biology and identify biomarkers linked to treatment response and resistance. Initial work will support oncology clinical research studies focused on antibody-drug conjugates and immunotherapy response prediction, as part of 10x's broader effort to explore potential future diagnostic applications of spatial technologies in oncology. Lunit SCOPE IO, which is for research use only, characterizes tumor and stromal regions, immune-cell distribution, tertiary lymphoid structures and other tumor microenvironment features to complement molecular profiling.
10x Genomics (Nasdaq: TXG) reported that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are licensed from Roche Sequencing Solutions. The jury upheld all three patents as valid and enforceable and awarded 10x Genomics over $4.8 million in damages, based on a 14% royalty rate on Parse’s U.S. sales of Evercode Whole Transcriptome products from February 2021 through June 30, 2026. According to 10x Genomics, it will seek enhanced damages, attorneys’ fees, and a permanent U.S. injunction against further infringement in post-trial proceedings.
10x Genomics (Nasdaq: TXG) reported second quarter 2026 revenue of $151.0 million, down from $172.9 million a year earlier. Excluding non-recurring patent litigation settlement revenue in both periods, revenue rose 3% to $149.4 million. Gross margin improved to 74% from 72%, helped by lower manufacturing costs, $2.6 million of tariff refunds and reduced inventory write-downs.
Operating expenses increased to $132.1 million, driven by a much smaller gain on settlement ($3.4 million versus $40.7 million in Q2 2025), resulting in an operating loss of $19.6 million and net loss of $17.9 million. According to 10x Genomics, products and services revenue grew to $149.1 million, while license and royalty revenue fell sharply to $1.9 million. The company ended June 30, 2026 with $552.0 million in cash, cash equivalents and marketable securities, raised its 2026 revenue guidance to $610–$630 million, completed the acquisition of Proteintech Genomics, and announced new multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital.
10x Genomics (Nasdaq: TXG) announced a multi-year research collaboration with Lausanne University Hospital (CHUV) to advance diagnostic applications of single cell and spatial technologies in cancer care. The study will use 10x’s Flex Apex and Xenium platforms, with plans to expand to Atera, on tumor samples from patients with advanced cancers evaluated by a clinical molecular tumor board.
The collaboration aims to identify clinically relevant biomarkers that may help predict treatment response and cancer prognosis across multiple solid tumors, including non-small cell lung, breast, bladder cancer and melanoma, and to explore how 10x technologies could complement current standard-of-care clinical assays.
10x Genomics (Nasdaq: TXG) will report its second quarter 2026 financial results for the period ended June 30, 2026 after market close on Thursday, August 6, 2026. The company will host a public conference call and live webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments and outlook, with materials and the news release available on the investor section of its website and a webcast replay accessible for at least 45 days.
IQM Quantum Computers appointed Craig Ciesla, former 10x Genomics (Nasdaq: TXG) VP of Engineering, as Chief Technology Officer and Inés de Vega as Chief Scientist.
The company is preparing for a planned Nasdaq listing via merger with Real Asset Acquisition Corp (Nasdaq: RAAQ), supported by an upsized $146 million PIPE. IQM operates a vertically integrated quantum computing business and has sold 23 quantum computers to date.
10x Genomics (Nasdaq: TXG) announced a multi-year research collaboration with Cleveland Clinic to advance diagnostic applications for bladder cancer. The partners will use 10x's Flex Apex, Xenium and later Atera platforms to study advanced bladder cancer tumor samples.
The project aims to identify clinically relevant biomarkers predicting response to antibody-drug conjugates and immunotherapies by integrating single cell transcriptomics, spatial gene expression and protein measurements with clinical outcomes.